Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 3/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.54 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MLNR | O43193 | 2/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22839032 | 0.88 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3MLNRHRH3 | |
| SCHEMBL20165492 | 0.83 | SLC6A4 (0.42) | SLC6A4SLC6A2SLC6A3KDM4EHRH3 | |
| SCHEMBL20158436 | 0.83 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3KDM4E | |
| SCHEMBL17123796 | 0.82 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HRH3MEN1 | |
| SCHEMBL14612865 | 0.80 | HRH3 (0.46) | SLC6A4HRH3 | |
| SCHEMBL20012540 | 0.80 | CARM1 (0.47) | SLC6A4SLC6A2SLC6A3KDM4EHRH3 | |
| SCHEMBL13940565 | 0.79 | GRIN1 (0.46) | SLC6A4HRH3 | |
| SCHEMBL24317561 | 0.79 | SLC6A2 (0.49) | SLC6A4SLC6A2SLC6A3HRH3 | |
| SCHEMBL22361477 | 0.79 | KDM4E (0.43) | SLC6A4KDM4EMEN1KMT2A | |
| SCHEMBL17128677 | 0.79 | SLC6A2 (0.54) | SLC6A4SLC6A2SLC6A3MLNRHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2019-10-15 | — | — | US | disclosed |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2018-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10441581-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | SLC6A4 3586/4885SLC6A2 4053/4885SLC6A3 1858/4885 |
| US-20180133207-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, RAF1 | SLC6A4 3586/4885SLC6A2 4053/4885SLC6A3 1858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.